Health Guide
Compound Library
Plain-English summaries: what it is, what it was studied for, safety and regulatory status, plus mixing and dosing charts.
A modified IGF-1 used in lab research. It is biologically active, but muscle-building, recovery and anti-aging claims are not established, and it is not the approved IGF-1 medicine.
An experimental small molecule, not a peptide, that blocks the enzyme NNMT.
A three-amino-acid peptide from the end of alpha-MSH, studied for anti-inflammatory activity in experimental gut inflammation.
An experimental small molecule, not a peptide, that activates estrogen-related receptors (ERRs) involved in energy use.
A small peptide encoded by mitochondrial DNA and studied for cell survival, metabolism and aging.
An experimental "senolytic" peptide designed to trigger the removal of certain aging (senescent) cells.
A pegylated version of mechano growth factor peptide, discussed in muscle-repair research.
A shortened form of insulin-like growth factor 1 that is more potent than regular IGF-1 in some lab tests.
An experimental seven-amino-acid peptide that blocks the TREK-1 potassium channel, studied as a new approach to depression research.
A copper-binding tripeptide related to GHK-Cu, studied mainly for hair follicles.
A four-amino-acid bioregulator peptide studied in heart-tissue cultures and animals.
A two-amino-acid synthetic peptide studied in immune-cell and aging research.
A four-amino-acid research peptide studied in airway cells and experimental lung-injury models.
A short tripeptide marketed as a liver or digestive "bioregulator." The clearest published experiments involve kidney cells and older rats, not liver disease in people.
A research-product name marketed as a Semax-related nootropic.
An experimental peptide that damages cancer cell membranes in lab and animal studies.